Funding Source - FDA OOPD
FDA-approved products for patients with unresectable or metastatic GIST include therapies
such as imatinib and sunitinib. Although there are FDA-approved products for the treatment of
advanced/metastatic GIST, these therapies are known to be ineffective in the
SDH-mutant/deficient subtype and no known effective therapies exist.
The purpose of this study is to investigate SDH-Mutant/Deficient Gastrointestinal Stromal
cancer's response to the drug Temozolomide (TMZ) and aim to improve patient outcomes.
Temozolomide is approved by the FDA for the treatment of newly diagnosed glioblastoma
multiforme (GBM) and refractory anaplastic astrocytoma cancers.
Temozolomide is considered experimental because it is not approved by the FDA for the
treatment of SDH-Mutant/Deficient Gastrointestinal Stromal Tumor.